The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients

Journal of the American Medical Directors Association

Volumn 4, Issue 4, 2003, Pages 189-194

  Kinon, Bruce J ^a   Stauffer, Virginia L ^a   McGuire, Hillary C ^a   Kaiser, Christopher J ^a   Dickson, Ruth A ^a,b   Kennedy, John S ^c  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic; Elderly; Prolactin

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE;

AGED; AGITATION; ARTICLE; BEHAVIOR DISORDER; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; FEMALE; HUMAN; HYPERPROLACTINEMIA; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NURSING HOME; PROLACTIN BLOOD LEVEL; RATING SCALE; SYMPTOM;

EID: 0041632225     PISSN: 15258610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-8610(04)70344-8     Document Type: Article

References (41)

1. Parnetti L, Amici S, Lanari A, et al. Pharmacological treatment of non-cognitive disturbances in dementia disorders. Mech Ageing Dev 2001;122:2063-2069.
2. Biller BMK, Luciano A, Crosignani PG, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999;44:1075-1084.
3. Knegtering H, Lambers PA, Prakken G, et al. Serum prolactin levels and sexual dysfunctions in antipsychotic medication, such as risperidone: A review. Acta Psychiatr Scand 2000;12:19-26.
4. Halbreich U, Rojansky N, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995;57:485-491.
5. NIH Consensus Development Panel on Osteoporosis Prevention DaT. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795.
6. Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes. Schizophr Bull 1996;22:447-454.
7. Klibanski A, Neer RM, Beitins IZ, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med 1980;303:1511-1514.
8. Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 2002;36:143-164.
9. Rubin RT, Porter JC. Involvement of hypothalamic dopamine in the regulation of prolactin secretion. Horm Res 1985;22:142-152.
10. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997;154:457-465.
11. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: Acute-phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-137.
12. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123.
13. Arvanitis L, Miller BG. Multiple fixed doses of Seroquel in patients with acute exacerbation of schizophrenia. Biol Psychiatry 1997;42:233-246.
14. Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18:296-304.
15. David S, Taylor C, Kinon BJ, et al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22:1085-1096.
16. Casey DE. Extrapyramidal syndromes and new antipsychotic drugs: Finding in patients and non-human primate models. Br J Psychiatry 1996; 168(suppl 29):32-39.
17. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999;45:403-411.
18. Lee HS, Kim CH, Song DH, et al. Clozapine does not elevate serum prolactin levels in healthy men. Biol Psychiatry 1995;38:762-764.
19. Kane JM, Cooper TB, Sachar EJ, et al. Clozapine: Plasma levels and prolactin response. Psychopharmacology 1981;73:184-187.
20. Borison RL, Arvanitis LA, Miller BG. ICI 204, 636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996;16:158-169.
21. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. Arch Gen Psychiatry 1997;54:549-557.
22. Crawford AM, Beasley C Jr, Tollefson G. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26:41-54.
23. Wright P, Birkett M, Ferchland I, et al. A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients. Eur Neuropsychopharmacol 2000;10(suppl):304.
24. Kinon BJ, Gilmore JA, Liu H. Prevalence of hyperprolactinemia in a large cohort of patients with schizophrenia treated with conventional antipsychotic drugs or risperidone, February 26, 2002. Davos, Switzerland: Eleventh Biennial Winter Workshop on Schizophrenia.
25. Dickson RA, Dalby JT, Williams R, et al. Risperidone, induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995;152:1102-1103.
26. Kinon BJ, Basson BR, Wang J, et al. Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone, October 27, 2000. Philadelphia: Institute of Psychiatric Services.
27. Kinon BJ, Targum SD, Basson BR, et al. Olanzapine in the management of behavioral disturbances and/or psychosis in demented nursing home patients. Psychosomatics 2001;42:176.
28. Streim JE, Katz IR. Federal regulations and the care of patients with dementia in the nursing home. Med Clin North Am 1994;78:895-905.
29. Hanning I, Seth J, Bacon RR, et al. Progress in immunoassays for serum prolactin: Evidence from the UK External Quality Assessment Scheme (EQAS) 1980-1989. Ann Clin Biochem 1991;28(Pt 1):91-97.
30. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
31. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol 1989;44:M77-M84.
32. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Publication ADM 76-338 ed. Bethesda, MD: U.S. Department of Health, Education and Welfare, 1976.
33. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients by the clinician. J Psychiatr Res 1975;12:189-198.
34. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418.
35. Satterlee WO, Beasley CM, Tollefson GD, et al. Preclinical and clinical observations of olanzapine (a new antipsychotic). Psychopharmacol Bull 1994;30:638.
36. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-369.
37. Clemens JA, Smalstig EB, Sawyer BD. Antipsychotic drugs stimulate prolactin release. Psychopharmacology 1974;40:123-127.
38. Cohen-Mansfield J, Taylor L, Woosley RL, et al. Relationships between psychotropic drug dosage, plasma drug concentration, and prolactin levels in nursing residents. Ther Drug Monit 2000;22:688-694.
39. Spitzer M, Sajjad R, Benjamin F. Pattern of development of hyperprolactinemia after initiation of haloperidol therapy. Obstet Gynecol 1998; 91:693-695.
40. Magharious W, Goff DC, Amico E. Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Res 1998;77:159-166.
41. Smith S, Wheeler MJ, Murray R, et al. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002;22:109-114.